Hypertension—persistently elevated blood pressure—is a major cardiovascular risk factor affecting over one billion people globally. Treatment aims to reduce target-organ damage and prevent stroke, MI, and kidney disease. First-line medications are highly effective; emerging regenerative approaches focus on endothelial repair and sympathetic-nerve remodelling.
ACE inhibitors (lisinopril, ramipril) and angiotensin-II-receptor blockers (losartan, valsartan) reduce vasoconstriction and protect the kidneys, forming the foundation of hypertension management. Calcium-channel blockers (amlodipine, diltiazem) are equally potent with excellent tolerability. Thiazide diuretics (hydrochlorothiazide) remain first-line and address volume overload. Beta-blockers (metoprolol, bisoprolol) lower heart rate and contractility, especially beneficial post-MI. Alpha-blockers and central-acting agents (methyldopa) are second-line. Most patients require two or more agents. Lifestyle—sodium restriction, weight loss, regular aerobic exercise, and stress reduction—is foundational. Resistant hypertension may benefit from renal-artery denervation (catheter-based ablation) or spironolactone addition.
DASH diet (Dietary Approaches to Stop Hypertension) reduces systolic BP by 8–14 mmHg through potassium, calcium, and fibre. Sodium restriction to <2.3 g/day is guideline-recommended. Meditation, biofeedback, and yoga lower BP through parasympathetic activation. Hawthorn, hibiscus tea, and coenzyme Q10 show modest benefits in small trials but should not replace medications.
Stem-cell therapies are being studied for endothelial-dysfunction repair and autonomic-nerve remodelling in resistant hypertension. Mesenchymal stem cells may reduce vascular stiffness and restore nitric-oxide production. These approaches remain investigational and should accompany, not replace, guideline-based antihypertensive therapy. See candidacy criteria for trial participation.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| ACE inhibitor (lisinopril, ramipril) | Standard | Strong | €100–250/year | Low | None |
| Angiotensin-II-receptor blocker (losartan, valsartan) | Standard | Strong | €120–280/year | Low | None |
| Calcium-channel blocker (amlodipine, diltiazem) | Standard | Strong | €90–200/year | Low | None |
| Thiazide diuretic (hydrochlorothiazide) | Standard | Strong | €50–150/year | Low | None |
| DASH diet + sodium restriction + aerobic exercise | Alternative | Strong | €0 | Low | None |
| Renal-artery denervation (catheter-based) | Standard | Moderate | €8,000–12,000 | Medium | 1 week |
| Endothelial-repair stem-cell therapy (resistant HTN) | Regenerative | Investigational | €14,000–30,000 (trial-dependent) | Medium | 2 weeks |
Most people do require lifelong therapy. Significant weight loss or intensive lifestyle modification may reduce doses, but hypertension rarely resolves completely without pharmacotherapy.
BP remaining above goal despite three medications at adequate doses (or requiring four or more agents). Stem-cell trials are exploring options for this challenging subset.
Stem-cell therapies are investigational and not ready to replace medications. They are being researched as adjuncts for resistant or refractory cases.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita